CRIS Current Research Information System

BARTOLETTI, DANIELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 707
EU - Europa 506
AS - Asia 202
AF - Africa 42
SA - Sud America 2
OC - Oceania 1
Totale 1.460
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 704
SE - Svezia 114
IT - Italia 96
DE - Germania 79
GB - Regno Unito 76
SG - Singapore 63
IN - India 55
IE - Irlanda 43
VN - Vietnam 33
CN - Cina 28
TG - Togo 22
FR - Francia 21
RU - Federazione Russa 18
FI - Finlandia 15
CI - Costa d'Avorio 13
CH - Svizzera 10
JO - Giordania 9
BE - Belgio 7
BG - Bulgaria 7
EE - Estonia 5
HK - Hong Kong 4
NG - Nigeria 4
PL - Polonia 4
TR - Turchia 4
UA - Ucraina 4
CA - Canada 3
ZA - Sudafrica 3
AT - Austria 2
BR - Brasile 2
TW - Taiwan 2
AU - Australia 1
BD - Bangladesh 1
ES - Italia 1
GE - Georgia 1
HR - Croazia 1
HU - Ungheria 1
JP - Giappone 1
NL - Olanda 1
PK - Pakistan 1
RO - Romania 1
Totale 1.460
Salva come PNG Salva come JPEG
Città #
Chandler 121
Southend 69
Fairfield 64
Singapore 56
Ashburn 50
Dublin 43
Princeton 38
Dong Ket 32
Woodbridge 29
Houston 26
Bologna 24
Wilmington 24
Seattle 23
Cambridge 22
Lomé 22
Hyderabad 21
Ann Arbor 17
Redmond 15
Helsinki 14
Abidjan 13
Nanjing 12
New York 12
Berlin 11
Bremen 11
Santa Clara 11
Milan 10
Westminster 10
Amman 9
Bern 8
Turin 8
Brussels 7
Los Angeles 7
Sofia 7
Des Moines 6
Boydton 5
Redwood City 5
Saint Petersburg 5
San Diego 5
Abeokuta 4
Migliarino 4
Norwalk 4
Paris 4
Shenyang 4
Beijing 3
Mountain View 3
Munich 3
Olalla 3
San Francisco 3
Toronto 3
Andover 2
Bari 2
Central 2
Cernusco sul Naviglio 2
Chicago 2
Falls Church 2
Fiesole 2
Hefei 2
Hong Kong 2
Imola 2
Mannheim 2
Poggio Renatico 2
Rome 2
Taipei 2
Torino 2
Vienna 2
Warsaw 2
Abano Terme 1
Amsterdam 1
Bagnacavallo 1
Bonn 1
Budapest 1
Bühl 1
Canberra 1
Capo D'orlando 1
Catanzaro 1
Changchun 1
Charlotte 1
Clearwater 1
Cortona 1
Cutrofiano 1
Dearborn 1
Delhi 1
Faisalabad 1
Florence 1
Frankfurt am Main 1
Fremont 1
Haikou 1
Hanoi 1
Hebei 1
Hounslow 1
Izhevsk 1
Kuban 1
Lappeenranta 1
Leawood 1
Leeds 1
Leipzig 1
Limidi 1
Madrid 1
Medford 1
Melzo 1
Totale 978
Salva come PNG Salva come JPEG
Nome #
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 138
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 138
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 131
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 126
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 105
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 91
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 75
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 71
null 68
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 59
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 59
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 57
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 57
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 56
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 52
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 46
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia 36
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 35
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 33
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 26
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 19
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity 19
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 17
Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms 12
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 10
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study 7
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 5
Totale 1.548
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.923
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.923
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020156 0 0 0 14 18 20 23 28 22 13 11 7
2020/2021204 28 15 5 1 3 14 6 25 37 4 9 57
2021/2022349 5 13 13 33 25 18 8 32 16 31 91 64
2022/2023478 35 58 30 63 44 48 12 28 97 14 26 23
2023/2024173 9 38 18 18 14 22 2 14 4 15 8 11
2024/2025119 59 59 1 0 0 0 0 0 0 0 0 0
Totale 1.548